• BioMarin Pharmaceutical recently reported that its Phase 3 CANOPY-HCH-3 trial of VOXZOGO in children with hypochondroplasia met its primary and key secondary endpoints, showing a statistically significant improvement in annualized growth velocity and arm span with a safety profile consistent with prior use in achondroplasia.
• Because there are currently no approved medicines for hypochondroplasia, these data and the planned supplemental FDA filing could meaningfully extend VOXZOGO’s reach into an additional rare growth disorder population.
• We’ll now examine how VOXZOGO’s successful hypochondroplasia Phase 3 trial and upcoming regulatory submissions may reshape BioMarin’s existing investment narrative.

Uncover the next big thing with 24 elite penny stocks that balance risk and reward.

BioMarin Pharmaceutical Investment Narrative Recap

For BioMarin to make sense in your portfolio, you need to believe in its rare-disease focus and VOXZOGO’s role as a core growth driver, while accepting the risks of high spending and regulatory dependence. The hypochondroplasia Phase 3 win strengthens the VOXZOGO story and could become a meaningful new label, but the most immediate catalyst remains VOXZOGO’s sNDA for full achondroplasia approval, with regulatory and pricing pressure still the biggest near term overhangs.

Among recent updates, BioMarin’s raised 2026 revenue guidance to US$3,825 million to US$3,925 million stands out in context of the VOXZOGO data. The guidance lift came before the hypochondroplasia Phase 3 readout, so investors now have a fresh clinical upside signal on top of already higher sales expectations, even as elevated R&D and SG&A spend and the planned Amicus acquisition financing keep margin and earnings risk in clear view.

Yet behind these promising VOXZOGO results, there is still the underappreciated risk that tighter global rare disease pricing could materially affect BioMarin’s ability to...

BioMarin Pharmaceutical's narrative projects $4.9 billion revenue and $1.3 billion earnings by 2029.

Uncover how BioMarin Pharmaceutical's forecasts yield a $89.96 fair value, a 63% upside to its current price.

Exploring Other Perspectives

While the baseline view emphasizes cost pressure and concentration risk, the most bullish analysts were already factoring in roughly US$4.2 billion of revenue and US$1.4 billion of earnings by 2028, so this VOXZOGO win could either support that optimism or force you to reassess how confident you really are in those assumptions.

Explore 4 other fair value estimates on BioMarin Pharmaceutical - why the stock might be worth over 3x more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your BioMarin Pharmaceutical research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free BioMarin Pharmaceutical research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate BioMarin Pharmaceutical's overall financial health at a glance.

Contemplating Other Strategies?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.